HTI-1066

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameHTI-1066
Drug Alias NameHTI-1066
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Hepatocyte growth factor receptor
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJiangsu Hengrui Medicine Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A